UK-based biotech advancing immunotherapeutic antimicrobial programs. Developing CTX-187 (ABX-01 programme), a broad-spectrum immunotherapeutic designed to treat multidrug-resistant Gram-negative bacterial infections using a dual mechanism of action.
Investment Rounds
Capital activity and funding progression
| Amount | Date | Round |
|---|---|---|
| €5.1 M | Jul, 2025 | unspecified |
| £6 M | Feb, 2026 | series-a |
Industries
Frequently Asked Questions
Where is Centauri Therapeutics located?
Centauri Therapeutics is located in Macclesfield, United Kingdom.
What industries does Centauri Therapeutics operate in?
Centauri Therapeutics operates in the following industries: biotechnology, healthcare, antimicrobials.
How much total funding has Centauri Therapeutics raised?
Centauri Therapeutics has raised a total of $11,100,000.
Who are the investors in Centauri Therapeutics?
The investors in Centauri Therapeutics are: CARB-X, AMR Action Fund, Boehringer Ingelheim Venture Fund, Evotec SE, Novo Holdings REPAIR Impact Fund.
What is the primary focus of Centauri Therapeutics?
Centauri Therapeutics is a biotechnology company dedicated to discovering and developing novel anti-infectives to treat life-threatening diseases, specifically focusing on the global challenge of antimicrobial resistance.
What is the Alphamer technology platform used by Centauri Therapeutics?
The Alphamer platform is a proprietary technology from Centauri Therapeutics that uses chemically synthesized molecules to redirect a patient's own pre-existing antibodies to target and destroy specific pathogens.
Where are the headquarters of Centauri Therapeutics located?
Centauri Therapeutics is based at Discovery Park in Sandwich, Kent, United Kingdom, which serves as a hub for its research and development activities.
Which types of infections does Centauri Therapeutics aim to treat?
Centauri Therapeutics targets serious, multi-drug resistant bacterial infections, including those caused by high-priority pathogens like Pseudomonas aeruginosa.
Who is the Chief Executive Officer of Centauri Therapeutics?
Centauri Therapeutics is led by Dr. Jennifer Schneider, who serves as the Chief Executive Officer and brings extensive experience in the biotechnology and anti-infectives sectors.